Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Furiex Pharmaceuticals, Inc. Stockholders

NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP is investigating potential claims against the Board of Directors of Furiex Pharmaceuticals, Inc. (“Furiex” or the “Company”) (NASDAQ:FURX) concerning the proposed acquisition of the Company by Forest Laboratories, Inc. (“Forest”) (NYSE:FRX). Under the terms of the definitive merger agreement, Furiex stockholders will receive $95 per share in cash and up to $30 per share in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex’s lead product, as a controlled drug following FDA approval.